Physician profile
Bryan Sean Smithson
NPI 1336377464
$1,819.13
in general payments reported to CMS, 2019-2025
22 companies · $437 in 2025
The $437 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $30.69 · 2021: $162 · 2022: $423 · 2023: $426 · 2024: $341 · 2025: $437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,203.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $261.15 | 2022-2025 | |
| Novo Nordisk INC | $256.07 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $152.58 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Grifols USA, LLC | $152.29 | 2022-2023 | Prolastin-C Liquid |
| Lilly USA, LLC | $129.21 | 2020-2023 | Mounjaro |
| E.R. Squibb & Sons, L.L.C. | $120.94 | 2022-2024 | Eliquis |
| Astrazeneca Pharmaceuticals LP | $117.19 | 2021-2025 | Breztri, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $107.25 | 2021-2024 | |
| Amgen INC. | $76.47 | 2024-2025 | Otezla, Repatha, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.45 | 2022 | |
| Sumitomo Pharma America, INC. | $57.67 | 2025 | Gemtesa |
| Astellas Pharma US INC | $50.98 | 2024-2025 | Veozah |
| Exact Sciences Corporation | $42.91 | 2025 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $42.09 | 2022 | |
| Merck Sharp & Dohme LLC | $40.90 | 2023 | Belsomra |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $27.62 | 2025 | Omnipod |
| Janssen Pharmaceuticals, INC | $25.18 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $24.77 | 2021 | |
| Amarin Pharma, INC. | $18.86 | 2021 | |
| Abbvie INC. | $15.24 | 2023 | Dalvance |
| Medtronic, INC. | $14.36 | 2024 | Minimed 780g |
| Aimmune Therapeutics, INC. | $13.95 | 2025 | Zenpep |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Smithson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.